Literature DB >> 2477832

Contractile properties of human prostate adenomas and the development of infravesical obstruction.

D I Gup1, E Shapiro, M Baumann, H Lepor.   

Abstract

The contractile response of human prostate adenomas to KCl, phenylephrine (alpha 1 adrenergic agonist), UK 14304 (alpha 2 adrenergic agonist), and carbachol (muscarinic cholinergic agonist) was evaluated in tissue specimens obtained from men with symptomatic and asymptomatic BPH. Prostate specimens were obtained from 5 men with asymptomatic BPH undergoing cystoprostatectomy, 11 men with symptomatic BPH undergoing open prostatectomy, and 11 men with symptomatic BPH undergoing transurethral resection of the prostate (TURP). Quantitative symptom score analysis and urinary flow rate determination documented the absence of bladder outlet obstruction in men undergoing cystoprostatectomy and confirmed the presence of bladder outlet obstruction in men undergoing prostatectomy. The magnitude of the contractile response (Emax) and the potency of phenylephrine-induced contractions (EC50) in prostatic preparations obtained from men with symptomatic and asymptomatic BPH were similar. The IC50 for the inhibition of phenylephrine-induced contractions by prazosin was 3.2 nM, confirming that phenylephrine-induced contraction in the human prostate is mediated by the alpha 1 adrenoceptor. The contractile responses of prostate adenomas to muscarinic cholinergic and alpha 2 agonists were negligible. This study demonstrates that the development of bladder outlet obstruction in men with BPH is not related to alterations in the functional response of the smooth muscle component of the prostate adenoma.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2477832     DOI: 10.1002/pros.2990150204

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  15 in total

Review 1.  The role of 5-alpha-reductase inhibition as monotherapy in view of the MTOPS data.

Authors:  Jaspreet S Sandhu; Alexis E Te
Journal:  Curr Urol Rep       Date:  2004-08       Impact factor: 3.092

2.  The residual nonadrenergic contractile response to nerve stimulation of the mouse prostate is mediated by acetylcholine but not ATP in a comparison with the mouse vas deferens.

Authors:  Carl W White; Jennifer L Short; John M Haynes; Richard J Evans; Sabatino Ventura
Journal:  J Pharmacol Exp Ther       Date:  2010-08-19       Impact factor: 4.030

Review 3.  Combination therapy for the pharmacological management of benign prostatic hyperplasia: rationale and treatment options.

Authors:  Jaspreet S Sandhu; E Darracott Vaughan
Journal:  Drugs Aging       Date:  2005       Impact factor: 3.923

4.  Pathophysiology of lower urinary tract symptoms in the aging male population.

Authors:  Herbert Lepor
Journal:  Rev Urol       Date:  2005

5.  Pathophysiology of benign prostatic hyperplasia in the aging male population.

Authors:  Herbert Lepor
Journal:  Rev Urol       Date:  2005

Review 6.  Novel drug targets for the pharmacotherapy of benign prostatic hyperplasia (BPH).

Authors:  S Ventura; V l Oliver; C W White; J H Xie; J M Haynes; B Exintaris
Journal:  Br J Pharmacol       Date:  2011-07       Impact factor: 8.739

7.  Pathophysiology, epidemiology, and natural history of benign prostatic hyperplasia.

Authors:  Herbert Lepor
Journal:  Rev Urol       Date:  2004

8.  A possible role of decreased relaxation mediated by beta-adrenoceptors in bladder outlet obstruction by benign prostatic hyperplasia.

Authors:  T Tsujii; H Azuma; T Yamaguchi; H Oshima
Journal:  Br J Pharmacol       Date:  1992-11       Impact factor: 8.739

Review 9.  Alpha1-, alpha2- and beta-adrenoceptors in the urinary bladder, urethra and prostate.

Authors:  Martin C Michel; Wim Vrydag
Journal:  Br J Pharmacol       Date:  2006-02       Impact factor: 8.739

10.  Therapeutic options in the treatment of benign prostatic hyperplasia.

Authors:  Jaspreet S Sandhu
Journal:  Patient Prefer Adherence       Date:  2009-11-03       Impact factor: 2.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.